Sweden's $80B Giant Just Dumped Tesla -- Here's Why It Could Spark a Bigger Investor Revolt
Swedens largest insurer just dropped Tesla (NASDAQ:TSLA). The reason? A clash over workers' rights thats been quietly brewing for months.
Folksam, managing more than $80 billion in assets, sold its $160 million stake after tryingtwiceto push Teslas leadership toward collective bargaining agreements for Swedish mechanics. No dice. Tesla, led by Elon Musk, insists its employee benefits are already competitive. But that wasnt enough for Folksam. No improvement has been seen, said Marcus Blomberg, the insurers head of asset management and sustainability. Translation: we tried engagement, it didnt work, were out.
This isnt just about one Scandinavian fund selling a fraction of a percent. Its a warning shot. In ESG-heavy markets like the Nordics, labor standards are non-negotiableand investors are willing to walk. If others follow Folksams lead, Tesla could face more pressure in Europe, not just from unions, but from capital looking for companies that match their values.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy, and steps the Company is taking to strengthen the safety profile in non-ambulatory patients. These steps follow a second reported case of acute liver failure (ALF) resulting in death. The cases of ALF to date have both occurred in non-ambulatory individuals with Duchenne. Sarepta extends its deepest sympathies to the affected families and care teams. Key Safety Initiatives Evaluating and Enhancing Immunosuppressive Regimen: As part of a comprehensive review of safety data, Sarepta is taking proactive steps to mitigate the risk of acute liver failure in non-ambulatory patients. Sarepta is working to immediately convene an independent group of leading experts in Duchenne and liver health to consider an enhanced immunosuppression regimen for ELEVIDYS. This panel will evaluate data and assess our proposed regimen, which includes sirolimus and is supported by preclinical data demonstrating the effectiveness of additional immunosuppression in moderating liver enzyme elevations, a key factor in mitigating potential safety events. Sarepta will share the panel's recommendations with the U.S. Food & Drug Administration (FDA), and implementation of any new regimen will be subject to FDA guidance and allowance. Suspending Shipments of ELEVIDYS for Non-Ambulatory Patients: Sarepta is temporarily suspending shipments of ELEVIDYS for non-ambulatory patients while an enhanced immunosuppressive regimen is evaluated, discussed with regulatory bodies, and put in place. For ambulatory patients, no treatment changes are being proposed and the current practice of administering corticosteroids before and after ELEVIDYS infusion, along with post-treatment monitoring, remains the same. ENVISION Study Paused: Sarepta has voluntarily paused dosing in the ENVISION clinical study (also known as Study SRP-9001-303). FDA concurs with this action. The pause will allow for the evaluation of a protocol amendment to incorporate an enhanced immunosuppressive regimen for the non-ambulatory patient cohort and incorporate any additional feedback from the FDA. Regulatory alignment is needed before screening and dosing in ENVISION may resume. ENVISION is a global, randomized, double-blind, placebo-controlled trial evaluating ELEVIDYS in older ambulatory and non-ambulatory individuals living with Duchenne muscular dystrophy. In the U.S., it serves as the confirmatory trial required under the FDA's accelerated approval pathway for non-ambulatory patients. 'Our paramount priority is the safety and well-being of the patients we serve. We are taking immediate, decisive steps to better understand and mitigate the risk of acute liver failure, including enhancing the immunosuppressive regimen, for those with Duchenne who are non-ambulatory,' said Louise Rodino-Klapac, Ph.D., chief scientific officer and head of research & development, Sarepta. 'We are deeply saddened by the loss of a second patient and extend our heartfelt condolences to the patient's family and his care team during this incredibly difficult time. Duchenne muscular dystrophy is a devastating disease that profoundly affects lives and often cuts them far too short. With more than 900 individuals treated to-date, we know how much hope families place in new treatment options like ELEVIDYS – and we are committed to honoring that hope by acting swiftly, guided by scientific rigor and the insights of leading experts, to strengthen safety for all future patients.' Commitment to Long-Term Safety and Understanding Sarepta remains committed to a thorough approach and the highest standards of patient safety and scientific rigor. The event has been reported to FDA and global health authorities and will inform ongoing discussions around a potential label update to reflect the risk of severe ALF and additional immune management strategies for non-ambulatory patients. While elevated liver enzymes are a known class effect of all AAV-based gene therapies, the exact mechanism behind AAV-related liver toxicity remains unclear. Current evidence suggests it is likely driven by an adaptive immune response. The Company will provide additional updates as appropriate. Investor Conference Call Details Sarepta will be hosting a conference call and webcast to discuss this update and provide an update on the Company's business on Monday, June 16, 2025, at 8:00 am Eastern time. The event will be webcast live under the investor relations section of Sarepta's website at: and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone. About ELEVIDYS (delandistrogene moxeparvovec-rokl) ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the DMD gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle. ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age. For patients who are ambulatory and have a confirmed mutation in the DMD gene For patients who are non-ambulatory and have a confirmed mutation in the DMD gene. The DMD indication in non-ambulatory patients is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). IMPORTANT SAFETY INFORMATION CONTRAINDICATION: ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene. WARNINGS AND PRECAUTIONS: Infusion-related Reactions: Infusion-related reactions, including hypersensitivity reactions and anaphylaxis, have occurred during or up to several hours following ELEVIDYS administration. Closely monitor patients during administration and for at least 3 hours after the end of infusion. If symptoms of infusion-related reactions occur, slow, or stop the infusion and give appropriate treatment. Once symptoms resolve, the infusion may be restarted at a lower rate. ELEVIDYS should be administered in a setting where treatment for infusion-related reactions is immediately available. Discontinue infusion for anaphylaxis. Acute Serious Liver Injury: Acute serious liver injury has been observed with ELEVIDYS, and administration may result in elevations of liver enzymes (such as GGT, GLDH, ALT, AST) or total bilirubin, typically seen within 8 weeks. Patients with preexisting liver impairment, chronic hepatic condition, or acute liver disease (e.g., acute hepatic viral infection) may be at higher risk of acute serious liver injury. Postpone ELEVIDYS administration in patients with acute liver disease until resolved or controlled. Prior to ELEVIDYS administration, perform liver enzyme test and monitor liver function (clinical exam, GGT, and total bilirubin) weekly for the first 3 months following ELEVIDYS infusion. Continue monitoring if clinically indicated, until results are unremarkable (normal clinical exam, GGT, and total bilirubin levels return to near baseline levels). Systemic corticosteroid treatment is recommended for patients before and after ELEVIDYS infusion. Adjust corticosteroid regimen when indicated. If acute serious liver injury is suspected, consultation with a specialist is recommended. Immune-mediated Myositis: In clinical trials, immune-mediated myositis has been observed approximately 1 month following ELEVIDYS infusion in patients with deletion mutations involving exon 8 and/or exon 9 in the DMD gene. Symptoms of severe muscle weakness, including dysphagia, dyspnea, and hypophonia, were observed. Limited data are available for ELEVIDYS treatment in patients with mutations in the DMD gene in exons 1 to 17 and/or exons 59 to 71. Patients with deletions in these regions may be at risk for a severe immune-mediated myositis reaction. Advise patients to contact a physician immediately if they experience any unexplained increased muscle pain, tenderness, or weakness, including dysphagia, dyspnea, or hypophonia, as these may be symptoms of myositis. Consider additional immunomodulatory treatment (immunosuppressants [e.g., calcineurin-inhibitor] in addition to corticosteroids) based on patient's clinical presentation and medical history if these symptoms occur. Myocarditis: Acute serious myocarditis and troponin-I elevations have been observed following ELEVIDYS infusion in clinical trials. If a patient experiences myocarditis, those with pre-existing left ventricle ejection fraction (LVEF) impairment may be at higher risk of adverse outcomes. Monitor troponin-I before ELEVIDYS infusion and weekly for the first month following infusion and continue monitoring if clinically indicated. More frequent monitoring may be warranted in the presence of cardiac symptoms, such as chest pain or shortness of breath. Advise patients to contact a physician immediately if they experience cardiac symptoms. Preexisting Immunity against AAVrh74: In AAV-vector based gene therapies, preexisting anti-AAV antibodies may impede transgene expression at desired therapeutic levels. Following treatment with ELEVIDYS, all patients developed anti-AAVrh74 antibodies. Perform baseline testing for presence of anti-AAVrh74 total binding antibodies prior to ELEVIDYS administration. ELEVIDYS administration is not recommended in patients with elevated anti-AAVrh74 total binding antibody titers greater than or equal to 1:400. Adverse Reactions: The most common adverse reactions (incidence ≥5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, and thrombocytopenia. Report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782). For further information, please see the full Prescribing Information. About Sarepta Therapeutics Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (Duchenne) and limb-girdle muscular dystrophies (LGMDs) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit or follow us on LinkedIn, X, Instagram and Facebook. Internet Posting of Information We routinely post information that may be important to investors in the 'For Investors' section of our website at We encourage investors and potential investors to consult our website regularly for important information about us. Forward-Looking Statements This statement contains 'forward-looking statements.' Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as 'believe,' 'anticipate,' 'plan,' 'expect,' 'will,' 'may,' 'intend,' 'prepare,' 'look,' 'potential,' 'possible' and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, research and development programs, clinical trials, ELEVIDYS, the potential benefits of an enhanced immunosuppression regimen in dosing in non-ambulatory patients, and expected plans and milestones, including providing additional updates as appropriate and engaging with regulators on an enhanced immunosuppressive regimen for dosing in non-ambulatory patients. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: different methodologies, assumptions and applications we use to assess particular safety or efficacy parameters may yield different statistical results, and even if we believe the data collected from clinical trials are positive, these data may not be sufficient to support approval by the FDA or other global regulatory authorities; success in clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful, and the results of future research may not be consistent with past positive results or with advisory committee recommendations, or may fail to meet regulatory approval requirements for the safety and efficacy of product candidates; our products or product candidates may be perceived as insufficiently effective, unsafe or may result in unforeseen adverse events; our products or product candidates may cause undesirable side effects that result in significant negative consequences following any marketing approval; we may not be able to comply with all FDA requests in a timely manner or at all; the possible impact of regulations and regulatory decisions by the FDA and other regulatory agencies on our business; and those risks identified under the heading 'Risk Factors' in our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company, which you are encouraged to review. Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained herein. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law.
Yahoo
an hour ago
- Yahoo
These 10 Used Cars Saw the Biggest Value Losses in 2025
These 10 Used Cars Saw the Biggest Value Losses in 2025 originally appeared on Autoblog. Used car prices are finally starting to creep upward after two years of post-pandemic corrections, but that doesn't mean every vehicle is gaining value. According to a new study by iSeeCars analyzing 2.4 million used sales in May 2024 and May 2025, several once-popular models are still dropping fast, especially in the electric vehicle and luxury categories. While the average 1- to 5-year-old used car now costs $32,317 — up 2% from a year ago — some vehicles lost 10% or more of their value. Here are the top 10 biggest losers in 2025. No vehicle lost more value this year than the Tesla Model S. Once a status symbol for early EV adopters, the average used Model S dropped 16% year-over-year, shedding $8,837 to land at an average price of $46,503. For a vehicle that started well north of $80,000 when new, that's a significant fall, and a reflection of how quickly electric luxury sedans are depreciating. While newer versions still offer jaw-dropping performance and range, the used market is clearly pulling back as buyers consider alternatives with newer battery tech or lower operating costs. The Model Y may be Tesla's best-selling vehicle, but it couldn't avoid a steep value drop. Over the past 12 months, the average used Model Y declined by 14.2%, losing $4,945 in value to settle at $29,789. Several factors likely contributed to the slide, including Tesla's repeated price cuts for new vehicles, increasing competition from other EV crossovers, and growing scrutiny of the brand's quality and leadership. For used buyers, however, this could be a golden opportunity to get into an EV with solid range at a relatively affordable price. With an average price of $75,644, the Porsche Taycan remains one of the priciest used EVs on the market, but it's also one of the fastest depreciating. Over the past year, Taycan prices dropped 12.7%, a raw-dollar loss of nearly $11,000. This luxury electric sedan wowed buyers with its performance when it launched, but newer rivals and rapid improvements in EV technology have chipped away at its appeal. Add in the fact that high repair and ownership costs are common with premium German vehicles, and it's no surprise the Taycan is struggling to hold its value. Not all of the biggest depreciation stories are luxury EVs. The Ford Explorer Hybrid lost 11.3% of its value over the past year, dropping by $4,044 to an average of $31,811. The hybrid version of this three-row SUV offers better fuel economy than its gas-only counterpart, but not enough to justify the price premium in the eyes of many used car shoppers. Combined with lackluster reviews and a competitive midsize SUV segment, the Explorer Hybrid has become a tougher sell on the used market. Even Tesla's most accessible model isn't immune to falling values. The Model 3 saw a 10.8% decline in resale value this year, losing $3,078 to reach an average used price of $25,361. For years, the Model 3 was seen as the EV market's standard bearer, but recent price drops on new versions and a flood of supply on the used market have pushed values lower. That's bad news for current owners, but for buyers, it means it's now possible to find a well-equipped used Model 3 for under $30,000. The Jeep Gladiator blends pickup utility with Wrangler off-road DNA, but its value hasn't held up. Over the past year, Gladiator prices dropped by 10.7%, translating to a $4,112 decline and bringing the average price down to $34,253. Part of the problem may be that the novelty of the Gladiator has worn off, and high fuel costs aren't doing rugged, body-on-frame trucks any favors. Still, for fans of outdoor adventure and removable doors, the falling price could be an invitation. The second Ford on this list is the Escape Plug-In Hybrid, which saw its average resale price drop by 10.7%, or $3,139, bringing it to $26,201. Plug-in hybrids occupy a strange space in the market — not quite electric, not quite gas — and that ambiguity seems to be hurting their resale values. While the Escape PHEV offers decent range and good efficiency, used car buyers may be opting for more straightforward hybrid or EV options instead. The Mercedes-Benz GLB is a boxy compact luxury SUV that offers surprising space for its size. Even with that practicality, the GLB lost 9.9% of its value in the past year, about $3,566, bringing its average price to $32,403. Luxury brands often depreciate quickly, especially in the entry-level segments, and the GLB appears to be no exception. Buyers who want a badge and some upscale features without paying new-car prices might find this model appealing — just be ready for premium maintenance costs. Maserati's Levante SUV combines exotic styling and performance with an SUV form factor, but its resale value is anything but stable. Prices dropped 9.5% year-over-year, falling by $4,663 to an average of $44,433. That's a steep decline for a vehicle that often carried six-figure MSRPs when new. As with many ultra-luxury brands, the Levante suffers from high depreciation, limited service networks, and concerns about long-term reliability — all of which make used buyers cautious. Rounding out the list is Tesla's largest vehicle, the Model X. This full-size SUV with its distinctive Falcon Wing doors saw a year-over-year price drop of 8.9%, or $5,292, putting the average price at $54,004. As new EV SUVs enter the market and Tesla's own software and hardware evolve quickly, older Model X units may start to feel dated. Still, for families seeking an all-electric ride with plenty of space and performance, a used Model X is now significantly more attainable than it was even a year ago. As a whole, used car prices are trending upward, but these 10 models show that the market is still volatile for certain segments. Electric vehicles, plug-in hybrids, and luxury SUVs are depreciating quickly, offering opportunities for savvy buyers willing to take on the risks that come with advanced tech or high-end nameplates. For sellers, the message is less optimistic. Anyone trying to offload a used Tesla, Maserati, or hybrid SUV may be in for a surprise, especially compared to the sky-high values seen in 2021 and 2022. But for buyers, particularly those hunting for an electric deal, 2025 may be the best time in years to find one. These 10 Used Cars Saw the Biggest Value Losses in 2025 first appeared on Autoblog on Jun 13, 2025 This story was originally reported by Autoblog on Jun 13, 2025, where it first appeared.
Yahoo
2 hours ago
- Yahoo
Is Broadcom Stock Your Ticket to Becoming a Millionaire?
Artificial intelligence (AI) is moving the needle significantly for Broadcom, and that trend could continue thanks to the huge addressable market it is serving. The chipmaker is now expected to clock stronger growth in the coming years thanks to AI. Broadcom's impressive growth and valuation make the stock an attractive buy. 10 stocks we like better than Broadcom › The artificial intelligence (AI) boom has supercharged Broadcom's (NASDAQ: AVGO) growth in recent quarters, with the company now getting a significant chunk of its revenue from selling custom processors and networking chips deployed by major cloud service providers in their data centers. The stock has made a big move in the past couple of months, jumping an impressive 41% as of this writing and going well past $1 trillion in market cap. The good part is that Broadcom is scratching the surface of a massive opportunity in the AI chip market that could help it sustain solid growth rates for a long time to come. Of course, buying just Broadcom and hoping that it will help you become a millionaire isn't a smart thing to do, as any cracks in the company's growth story could send the stock plunging. However, Broadcom looks like an ideal pick for investors aiming to construct a diversified million-dollar portfolio. Let's look at the reasons why. Broadcom released its fiscal 2025 second-quarter results (for the three months ended May 4) on June 5. Its revenue jumped 20% year over year to $15 billion, while adjusted earnings shot up at a stronger pace of 43%. AI played a key role in driving this robust growth. The company's AI revenue jumped 46% year over year to $4.4 billion, which means it's now getting almost 30% of its top line by supplying chips powering this technology. What's worth noting here is that Broadcom is anticipating further acceleration in its AI revenue in the current quarter, projecting $5.1 billion in revenue. That would be an improvement of 60% from the year-ago period. What's more, Broadcom CEO Hock Tan indicated on the latest earnings conference call that the company's AI revenue growth trajectory is sustainable. Tan remarked that the growth rate Broadcom is witnessing so far in fiscal 2025 "will presumably continue." That's not surprising, considering that Broadcom is now seeing stronger demand for its custom AI chips (known as XPUs) for inference purposes. Management says that the three existing customers who are deploying its custom chips in data centers for AI training remain firm in their infrastructure investment plans, despite the economic uncertainty created by the tariff war. At the same time, those three customers "are doubling down on inference in order to monetize their platforms," which is why the company anticipates "an acceleration of XPU demand into the back half of 2026 to meet urgent demand for inference on top of the demand we have indicated from training." A big reason why Broadcom should be able to sustain its impressive AI revenue growth rate is because of the massive addressable opportunity worth $60 billion to $90 billion that it sees for its AI chips by fiscal 2027 based on the three customers it's currently serving. Given that the company has generated $13.6 billion in revenue from sales of its AI chips in the first three quarters of the year, it still has a lot of room to grow in this market. That's especially true considering that another four hyperscalers are in negotiations with Broadcom for manufacturing custom AI processors. As a result, Broadcom may be sitting on a much larger AI-related addressable market, which explains why analysts have raised their growth expectations for the company following its latest results. Broadcom is trading at just under 38 times forward earnings as of this writing following its recent surge. While that may seem expensive at first, we have seen that the company's outstanding earnings growth justifies its rich valuation. Another important thing worth noting is that Broadcom's price/earnings-to-growth ratio (PEG ratio) based on its projected earnings growth for the next five years stands at just 0.66, according to Yahoo! Finance. The PEG ratio is a forward-looking valuation metric calculated by dividing a company's price-to-earnings ratio by its estimated annual earnings growth rate for the next five years. A reading of less than 1 means that the stock in question is undervalued, and Broadcom's multiple is well below that mark. All this makes Broadcom a solid growth stock to buy right now, since it seems built for terrific long-term upside and has the potential to contribute positively toward a million-dollar portfolio. Before you buy stock in Broadcom, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Broadcom wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $655,255!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $888,780!* Now, it's worth noting Stock Advisor's total average return is 999% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Harsh Chauhan has no position in any of the stocks mentioned. The Motley Fool recommends Broadcom. The Motley Fool has a disclosure policy. Is Broadcom Stock Your Ticket to Becoming a Millionaire? was originally published by The Motley Fool Se produjo un error al recuperar la información Inicia sesión para acceder a tu portafolio Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información
